Inge Basteleurs has practiced law for over 25 years : 5 years in private practice at Linklaters (De Bandt) in Belgium and in the UK, about 7 years in the (green) biotechnology industry at Bayer Bioscience in Belgium and 7 years in the biopharmaceutical industry at the publicly listed company, UCB SA in Belgium.

Inge started up Calexin at the end of 2012 as a novel business-oriented manner of practicing law. Since then Calexin has been successfully completing various projects in the life sciences and biotech sector. 

During the early part of her career, Inge worked in Belgium and the UK in the corporate, commercial and finance practice of an international law firm, handling as lead lawyer several M&A and corporate transactions.

At Bayer Bioscience, she worked closely with their research and development group which allowed her to expand her expertise in negotiations, intellectual property licensing (in and out) and collaborative partnerships. As such, she also managed several in- and out-licensing deals with US, EU, Asia or Latin American-based companies or universities. Another type of deal she managed for Bayer and Nunhems was the divestment or acquisition of several of their research activities / business units.

Inge then joined UCB to set up of the legal support for the International Major Markets (i.e. the world outside the US and Europe, "IMM") as part of the IMM Management Team. Her responsibilities got expanded when she was put in charge of the legal department that supported Business Development / M&A / Licensing, Global Finance and New Medicines (research). In this capacity, she was lead counsel on various deals, totaling over 5.6bn Euro. Inge became Secretary General of UCB SA. Her team organized all activities required of a publicly listed company (such as the shareholders' meeting, Board, Audit Committee, the discussions with financial authorities and other important players in this field, corporate governance etc). She was instrumental in setting up a corporate governance compliance program, an insider dealing program and a decision making RACI.

As the director of Calexin she handled amongst others the following projects:

• She set up the legal, compliance and intellectual property department for the EMEA HQ of a Japanese listed company, where she took on the role of General Counsel until such department was up and running. She completed the restructuring of the Haasrode site, won/settled several Intellectual Property litigations and successfully countered negative press coverage.
  
  
• As Data Privacy Officer, she handled the implementation of the GDPR for Belgium/Luxembourg for a major German listed medtech company and worldwide for a Belgian listed health and wellness company.
  
  
• She is currently compliance lead MENA and APAC and DPO for a Belgian listed pharmaceutical company, General Counsel and Chief Compliance Officer for a Belgian privately owned medtech company as well as DPO and legal advisor for a hospital network. She also sits on the Board of Directors of WGC Caleido-De Ridderbuurt.